H.C. Wainwright raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $30 and keeps a Buy rating on the shares after the FDA approved an update to the labeling for Filspari. The FDA agreed to reduce the frequency of liver function monitoring from monthly to every three months starting at treatment initiation, and to remove the pregnancy monitoring requirement, the analyst tells investors in a research note. The firm sees the move as creating a competitive advantage for Filspari.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Buy Rating Affirmed for Travere Therapeutics Amid Positive FDA Changes for Filspari
- Travere Therapeutics’ filspari granted FDA approval for REMS labeling
- Strategic Positioning and Growth Potential Drive Buy Rating for Travere Therapeutics
- Positive Growth Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Strategic Initiatives
- Travere Therapeutics price target raised to $34 from $32 at Citi